Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202199 | 0.82 | KMT2A (0.40) | OPRD1MEN1KMT2AOPRK1OPRM1 | |
| SCHEMBL3299615 | 0.79 | MAOB (0.53) | OPRD1KMT2AALDH1A1SLC6A9 | |
| SCHEMBL4438292 | 0.78 | OPRD1 (0.41) | OPRD1MEN1KMT2AOPRK1OPRM1 | |
| SCHEMBL4388699 | 0.78 | KMT2A (0.45) | OPRD1MEN1KMT2AOPRK1OPRM1 | |
| SCHEMBL2196605 | 0.77 | OPRL1 (0.44) | OPRD1MEN1KMT2AOPRK1OPRM1 | |
| SCHEMBL5225078 | 0.76 | MGLL (0.51) | OPRD1MEN1KMT2AOPRK1OPRM1 | |
| SCHEMBL7257984 | 0.76 | HSD11B1 (0.51) | OPRD1MEN1KMT2AOPRK1OPRM1 | |
| SCHEMBL27872585 | 0.76 | OPRD1 (0.40) | OPRD1MEN1KMT2AOPRM1 | |
| SCHEMBL27872584 | 0.76 | CTSK (0.47) | OPRD1MEN1KMT2A | |
| SCHEMBL3300275 | 0.73 | MGLL (0.51) | MEN1KMT2ASLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | OPRD1 4402/4885MEN1 3180/4885KMT2A 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.